Momenta Pharmaceuticals, Inc. (MNTA)

[Regulardoc]

MNTA appears to have less than 2 years of cash needs on hand. No significantly profitable current product after the Mylan approval and none on the horizon until at least 2021. Even if 40 mg is approved later this year, profits won't come close to meeting quarterly costs.

Clearly embedded with MYL but would have to "sell" its Glatopa franchise, which is unlikely to fetch much. Obvious buyer would be NVS, if they even have an interest in marketing the drug.

Comes down to its cash and any consequential science that they may have that MYL's other partners are lacking.